Long-term results of endovascular treatment of patients with coronary heart disease using various PCI technologies

Objective: the effectiveness and safety of endovascular treatment of coronary artery disease in coronary artery disease using various technologies of percutaneous coronary intervention (PCI) was evaluated — implantation of drug-coated metal stents, implantation of bioresorbable stenting scaffolds, the use of drug-coated coronary balloon catheters in the long- term period, 10 years after PCI.

Materials and methods: data obtained from 324 patients with coronary heart disease after PCI using the previously mentioned treatment methods. The endpoint was the loss of the target vessel lumen (TLF), a combination of cardiac death, myocardial infarction, and revascularization associated with the target vessel.

Results: the treatment of patients with coronary heart disease using implantation of drug-coated metal stents, bioresorbable stenting scaffolds or drug-coated coronary balloon catheters is safe and has low rates of cardiac mortality, myocardial infarction and revascularization of the target vessel in the long term. In cases where implantation of stents or scaffolds was contraindicated or impossible due to the small diameter of the artery, diffuse extended lesion and high risk of restenosis, angioplasty with a coronary balloon catheter with an antiproliferative drug coating takes place, showing positive long-term results.

1. Jia S, Liu Y, Yuan J. Evidence in Guidelines for Treatment of Coronary Artery Disease. Adv Exp Med Biol. 2020;1177:37-73. DOI: 10.1007/978-981-15-2517-9_2

2. Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(3):e4-e17. Erratum in: Circulation. 2022;145(11):e771. DOI: 10.1161/CIR.0000000000001039

3. Korobka V.L., Khripun A.V., Malevannyy M.V., Kulikovskikh Ya.V. The short-term and mid-term outcomes of percutaneous coronary intervention with implantation of bioresorbable vascular scaffolds for stemi treatment. Russian journal of endovascular surgery. 2015;2(1-2):58-68. eLIBRARY ID: 27640351 EDN: XGWEYF

4. Nathan A, Kobayashi T, Kolansky DM, Wilensky RL, Giri J. Bioresorbable Scaffolds for Coronary Artery Disease. Curr Cardiol Rep. 2017;19(1):5. DOI: 10.1007/s11886-017-0812-7

5. Brugaletta S, Garcia-Garcia HM, Onuma Y, Serruys PW. Everolimus-eluting ABSORB bioresorbable vascular scaffold: present and future perspectives. Expert Rev Med Devices. 2012;9(4):327-238. DOI: 10.1586/erd.12.17

6. Kereiakes DJ, Ellis SG, Metzger C, Caputo RP, Rizik DG, Teirstein PS, et al. 3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds: The ABSORB III Trial. J Am Coll Cardiol. 2017;70(23):2852-2862. DOI: 10.1016/j.jacc.2017.10.010

7. Kimura T, Kozuma K, Tanabe K, Nakamura S, Yamane M, Muramatsu T, et al. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J. 2015;36(47):3332-3342. DOI: 10.1093/eurheartj/ehv435

8. Brugaletta S, Gori T, Tousek P, Gomez-Lara J, Pinar E, Ortega-Paz L, et al. Bioresorbable vascular scaffolds versus everolimus-eluting metallic stents in patients with ST-segment elevation myocardial infarction: 5-year results of the BVS-EXAMINATION study. EuroIntervention. 2020;15(16):1436-1443. DOI: 10.4244/EIJ-D-19-00773

9. Brugaletta S, Gori T, Low AF, Tousek P, Pinar E, Gomez-Lara J, et al. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction). JACC Cardiovasc Interv. 2015;8(1 Pt B):189-197. Erratum in: JACC Cardiovasc Interv. 2015;8(3):503. DOI: 10.1016/j.jcin.2014.10.005.

10. Cassese S, Katagiri Y, Byrne RA, Brugaletta S, Alfonso F, Räber L, et al. Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents: a pooled analysis of individual patient data. EuroIntervention. 2020;15(16):1451-1457. DOI: 10.4244/EIJ-D-18-01080